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Abstract
Follow-up procedures vary among cancer registries in North America. US registries are funded by 
the Surveillance, Epidemiology, and End Results (SEER) Program and/or the National Program of 
Cancer Registries (NPCR). SEER registries ascertain vital status and date of last contact to meet 
follow-up standards. NPCR and Canadian registries primarily conduct linkages with local and 
national death records to ascertain deaths. Data on patients diagnosed between 2002 through 2006 
and followed through 2007 were obtained from 51 registries. Registries that met follow-up 
standards or, at a minimum, conducted linkages with local and national death records had 
comparable age-standardized five-year survival estimates (all sites and races combined): 63.9% 
SEER, 63.1% NPCR, and 62.6% Canada. Estimates varied by cancer site. Survival data from 
registries using different follow-up procedures are comparable if death ascertainment is complete 
and all nondeceased patients are presumed to be alive to the end of the study period.
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Population-based cancer survival is a necessary component to fully understand the burden of 
cancer in the population (1). Survival data can help measure access to and utilization of 
health-care services (2) and inform the need for cancer control activities aimed at reducing 
the cancer burden (3,4). Comparative analyses of survival have been used to motivate and 
evaluate cancer control activities between and within countries (4,5). Similar analyses in 
North America may inform cancer control activities at the national and local levels.
Population-based cancer registries throughout North America collect information on all 
residents diagnosed with cancer in their catchment areas including demographic data (birth 
date, race/ethnicity [United States only], sex), case data (date of diagnosis, primary site, 
histology, behavior, sequence number), and followup data (vital status [alive and dead], date 
of last contact, source of follow-up information, and cause of death for deceased patients) 
using standard procedures (6).
With financial support from their health agencies, there is a cancer registry in all 10 
Canadian provinces and 3 territories (7). All Canadian registries report demographic and 
case data to the Canadian Cancer Registry, a patient-based surveillance system maintained 
by Statistics Canada (8). In the United States, registries are supported through the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program (9) and the 
Centers for Disease Control and Prevention’s National Program of Cancer Registries 
(NPCR) (10). US registries report data to their respective federal funding programs. 
Between SEER and NPCR, there is a cancer registry in all 50 states and the District of 
Columbia (11). All Canadian and US registries are members of the North American 
Association of Central Cancer Registries (NAACCR).
Registries routinely perform death clearance by linking their incidence data with local death 
certificate records to identify cancer patients who were missed at the time of their diagnosis 
and follow back to obtain information relating to the decedent’s diagnosis. In addition, these 
linkages are also intended to give the registries the opportunity to record date and cause of 
death for deceased cancer patients (12). If no information related to an earlier diagnosis can 
be found, the cancer patient is registered as a death certificateonly (DCO) case and the date 
of death is recorded as the date of diagnosis.
Activities undertaken to obtain follow-up data can range from direct contact with cancer 
patients, their families, or physicians to indirect verification of vital status through 
computerized linkages with administrative databases such as those maintained by (in the 
United States) the Centers for Medicare and Medicaid Services, the Social Security 
Administration, licensing bureaus and voter registration offices (13).
Deaths are recorded in the province or state where the death occurs, and this information is 
forwarded if necessary to the vital records office in the jurisdiction where the person resided 
at the time of their death. However, the province or state where the death occurred may not 
be the same as where the patient was diagnosed and registered by the cancer registry. In this 
situation, linkage between the registry and their national repository of death certificate 
information [Statistics Canada’s Death Database (14) and Centers for Disease Control and 
Prevention’s National Death Index (NDI) (15)] can ascertain deaths that occur within the 
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country. These linkages do not provide follow-up information on living patients or patients 
who moved out of the country between the time of their diagnosis and death. Annually, 
Statistics Canada links the Canadian Cancer Registry to its Death Database (except for 
Quebec deaths due to legal limitations) and notifies the reporting registry of outof-province 
deaths. The SEER Program requires their registries to meet follow-up standards by reporting 
vital status and a date of last contact that is within 22 months of the date of their annual data 
submission to SEER for a minimum of 90% of all registered cancer patients, living and 
deceased (16). NPCR registries record vital status and the date of last contact as available, 
but the registries are not funded or required to meet follow-up standards. However, in 2008, 
NPCR and SEER arranged for NDI linkage services to be available at no additional cost to 
their registries to encourage the registries to comprehensively ascertain deaths within the 
United States. Most but not all NPCR and SEER registries are performing these linkages.
NAACCR compiles incidence data from all member registries through their annual Call for 
Data and publishes these data in Cancer in North America (17). NAACCR has developed 
criteria for evaluating and certifying cancer registries as having high-quality cancer 
incidence data (18). These data are aggregated for combined estimates of cancer incidence at 
the national level.
The extent and method of follow-up activities have been shown to affect the completeness 
of death ascertainment and the period that a cancer patient is at known or assumed risk of 
dying (19,20). Missing deaths can result in spuriously high survival estimates, whereas over- 
or under-estimating the time that a cancer patient is at risk of dying can raise or lower 
survival estimates (20). Therefore, different follow-up procedures may bias the comparison 
of survival estimates among registries.
The purpose of this study was to assess the effect of different follow-up procedures on five-
year survival estimates and develop criteria for identifying high-quality cancer survival data 
for inclusion in Cancer in North America.
Methods
Source of Data
In 2011, NAACCR requested follow-up information for all cases of invasive cancer 
diagnosed 1995 through 2009. Site and histology information were coded to the third edition 
of the International Classification of Diseases for Oncology and recoded to SEER site 
recodes (21,22). Registries were eligible for inclusion in this analysis if their incidence data 
met Cancer in North America publication criteria for diagnosis years 2002 through 2006 
(17), they consented to have their data included in this analysis, and they submitted follow-
up information through December 31, 2007. These years were selected to optimize the 
number of eligible registries. Cases diagnosed between July 1 through December 31, 2005 in 
the states of Alabama, Louisiana, Mississippi, and Texas were excluded due to problems 
with data collection following Hurricanes Katrina and Rita (23).
Record-level data were extracted for all patients diagnosed with an invasive primary cancer 
between the age of 15 and 99 years using the case listing function in SEER*Stat software 
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(Version 7.04, Information Management Services, Inc., Silver Spring, MD) and processed 
using SAS (Version 9.2, Cary, NC). In addition to the date of last contact reported by the 
cancer registry, an end-ofstudy date (December 31, 2007) was assigned to all nondeceased 
cases. Date of last contact was not altered for deceased cases. One Canadian registry 
(CAN01) assigned a reported follow-up date of December 31, 2009 for all nondeceased 
cancer patients.
The data were reloaded into SEER*Stat for analysis using SEER*Prep (Version 2.4.6, 
Information Management Services, Inc., Silver Spring, MD).
Data Evaluation
Registry data were grouped by country (Canada and United States) and within the United 
States (NPCR and SEER). Registries funded by both SEER and NPCR (California, Georgia, 
Kentucky, Louisiana, and New Jersey) were categorized as SEER because these registries 
are funded to meet SEER follow-up standards and their survival data have been published 
(24). The 51 participating registries were categorized as follows: Canada (Alberta, 
Manitoba, Nova Scotia, and Ontario); NPCR (Alabama, Alaska, Arizona, Arkansas, 
Colorado, Delaware, Florida, Idaho, Illinois, Indiana, Maine, Massachusetts, Michigan, 
Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New York, North 
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South 
Carolina, South Dakota, Texas, Virginia, Washington, West Virginia, Wisconsin, and 
Wyoming); and SEER (California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, 
Louisiana, New Jersey, New Mexico, Utah, and metropolitan-area registries in Detroit and 
Seattle). To maintain confidentiality, registries were identified by randomly assigned 
numeric values within country and by program. Data from NPCR01 to NPCR16 contained 
information from NDI for deaths that occurred in 2002 through 2007 (n = 14) and/or met 
SEER follow-up standards (n = 3).
Survival analyses were restricted to the first primary cancer diagnosed (only cancer 
diagnosed or the first of multiple primary [MP] cancers diagnosed) for each cancer patient, 
and excluded DCO and autopsy-only cases because these cases had no calculable survival 
interval. To estimate the percentage of cases that were excluded from the survival analyses, 
we evaluated the percentage of MP cancers using SEER MP coding rules (25) and the 
percentage of DCO (including autopsy-only) cases among first primary cancers. To evaluate 
the breadth of case finding activities conducted by each cancer registry, we estimated the 
percentage of microscopically confirmed (MC) cases among first primary non-DCO cases. 
A patient was considered to have complete follow-up information if they were deceased 
(any date) or alive with last follow-up date of January 1, 2008 or later. Data from SEER 
registries were considered the gold standard when evaluating data from Canada and NPCR 
because SEER registries are funded and required to meet follow-up standards.
Survival Analyses
Cases with missing age or sex were excluded. The survival interval for decedents was 
computed from the date of diagnosis to the date of death. Nondeceased cases contributed 
person-time at risk and were censored at the date of last contact as reported by the cancer 
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registry (reported alive survival) and at the end-of-study date (presumed alive survival). To 
obtain a more up-to-date survival estimates in months, the multiple-year cohort method was 
used, which included all patients diagnosed in the most recent years spanning the maximum 
duration (60 months) to be estimated (26).
All-cause (observed) survival is the percent of patients alive at some specified time after 
diagnosis following the identification of deaths from all causes. Relative survival (RS) 
estimates the probability of survival related to a specific cancer in the absence of other 
causes of death and is calculated as the ratio of all-cause survival among cancer patients 
with a specific cancer to the expected survival among the population with similar 
demographic characteristics [eg, age, sex, calendar year of death, race, and geographic area 
(27)]. For US registries, expected survival was derived from national life tables available in 
SEER*Stat. Provincial life tables were used for Canadian registries (28). Confidence 
intervals were calculated using a log (–[log]) transformation.
Survival estimates were age-standardized to the International Cancer Survival Standard 
using five age groups (29). For some combinations of registry, primary site, and age group, 
survival estimates could not be calculated because no cases were reported alive at the start of 
the 60th month. To avoid presenting missing survival estimates in this situation, 
unstandardized estimates were used for both reported and presumed alive survival. These 
estimates are identified by a caret (ˆ) in the figures.
Results
Table 1 presents data quality indicators for all cancers combined by registry. Values that fell 
plus or minus 1% outside the SEER range were noted by a double dagger symbol (‡) in the 
table. This error allowance is consistent with NAACCR evaluation methods (18). The 
percentage of MP cases reported (sequence number: ≥02) ranged from 13.6% to 19.1% 
among SEER registries; eight NPCR registries and two Canadian registries reported values 
below the SEER range. Among first primary cancers, the percentage of DCO cases ranged 
from 0.4% to 3.7% for SEER; no NPCR or Canadian registry had a value outside the SEER 
range. The percentage of total cases excluded ranged from 14.9% to 20.5% among SEER 
registries; five NPCR and two Canadian registries reported values below the SEER range. 
The percentage of MC first primary, non-DCO cases ranged from 93.3% to 96.9% for 
SEER; one NPCR registry (NPCR15) reported a value (100.0%) above the SEER range, and 
two Canadian registries reported values below the SEER range. The percentage of cases 
with complete followup information was 97.5%–99.6% for SEER, 30.8%–96.1% for NPCR, 
and 54.8%–100.0% among Canadian registries. All NPCR and two Canadian cancer 
registries reported lower percentages of complete follow-up than SEER registries. Three 
NPCR registries (NPCR06, NPCR10, and NPCR13) and two Canadian registries (CAN01 
and CAN02) reported follow-up that met SEER followup standards, although CAN01 
appeared to have assigned a uniform follow-up date to all nondeceased patients based on 
when the registry submitted their data to NAACCR.
Stacked bar charts (Figures 1A–D) show age-standardized fiveyear RS for four leading 
cancers by registry. The lighter shading shows the reported alive survival percent and the 
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final (black) bar width shows the presumed alive survival percent. Values greater than 1% 
above the SEER range for presumed alive survival were noted by an asterisk (*) in the 
figures. The range of presumed alive survival was as follows: female breast cancer (Figure 
1A) was 82.6%–94.1% for SEER, 83.3%–109.1% for NPCR, and 85.7%–86.3% for 
Canadian registries; prostate cancer (Figure 1B was) 94.7%–101.5% for SEER, 92.5%–
113.5% for NPCR, and 92.8%–97.7% for Canadian registries; cancers of the lung and 
bronchus (Figure 1C) were 13.4%–20.5% for SEER, 14.0%–46.0% for NPCR, and 13.9%–
20.7% for Canadian registries; and cancers of the colon and rectum (Figure 1D) were 
61.2%–69.2% for SEER, 58.9%–96.3% for NPCR, and 61.6%–64.1% for Canadian 
registries. Among registries who reported higher survival than SEER, all were NPCR. Of 
these registries, only two of seven for colorectal cancers, zero of three for breast cancer, zero 
of four for prostate cancer, and zero of nine for lung and bronchus cancers met SEER 
follow-up standards and/or included NDI linkage results in their datasets.
Visual inspection of Figures 1A-D shows that two NPCR registries (NPCR26 and NPCR31) 
reported the highest five-year presumed alive survival for all cancers examined. Visual 
inspection also suggests the extent of follow-up activities performed by each registry. For all 
SEER registries, reported alive survival nearly equaled the presumed alive survival. Two 
Canadian registry (CAN01 and CAN02) and three NPCR registries (NPCR06, NPCR10, and 
NPCR13) reported similar follow-up patterns, suggesting that they performed complete 
follow-up on living patients or assigned follow-up dates assuming that cases not known to 
be deceased were still alive. Data from two of these registries (NPCR10 and NPCR13) did 
not include NDI linkage results. For all remaining NPCR registries, variable differences 
were observed between reported alive and presumed alive survival.
RS (%) estimates in Tables 2 and 3 were based on data from 32 registries (all SEER and 
Canadian registries and NPCR01– NPCR16). These data covered 53.2% of the US 
population (statewide coverage) and 55.4% of the Canadian population (province-wide 
coverage), respectively. Table 2 shows age-standardized five-year, presumed alive RS and 
data quality indicators (%DCO and %MC) by registry. Survival estimates were noted in the 
table if they were 1% above the SEER range. The range of survival for female breast cancer 
was 82.6%–94.1% for SEER, 83.3%–94.1% for NPCR, and 85.7%–86.3% for Canadian 
registries. Survival for prostate cancer ranged from 94.7%–101.5% for SEER, 92.5%–
102.5% for NPCR, and 92.7%–97.9% for Canadian registries. For six registries (three SEER 
and three NPCR), presumed alive RS exceeded 100.0% for prostate cancer. The range of 
survival for cancer of the lung and bronchus was 13.4%–20.5% for SEER, 14.0%–20.1% for 
NPCR, and 13.9%–20.7% for Canadian registries. Survival for colorectal cancer ranged 
from 61.2% to 69.2% for SEER, 58.9% to 71.0% for NPCR, and 61.6% to 64.1% for 
Canadian registries. One NPCR registry (NPCR15) reported the highest (colorectal) or 
among the highest (breast, prostate, and lung) survival estimates of all registries and 100% 
MC cases for all four cancers. The %DCOs for this registry were within the SEER range for 
all four cancer sites.
Table 3 shows age-standardized five-year RS for all sites combined and 23 common 
cancers. SEER survival estimates are shown using both the reported alive and presumed 
alive survival. Survival for NPCR and Canada was computed using the presumed alive 
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survival estimates. For NPCR and SEER survival combined, reported survival time was 
used for all SEER registries and for three NPCR registries that met the SEER follow-up 
standard. Presumed alive survival estimates were used for the remaining 13 NPCR 
registries.
Among SEER registries, presumed alive survival estimates were marginally and consistently 
higher than reported alive survival estimates for all cancer sites examined; differences 
ranged from 0.1 (testis) to 1.5 (cervix) percentage points. Differences were higher for cancer 
sites with poor survival (stomach, pancreas, and liver cancer). Presumed alive survival 
estimates for all sites combined were 63.9% for SEER, 63.1% for NPCR, and 62.6% for 
Canada. Rates varied by cancer type and country and within the United States, by program. 
The absolute difference between SEER and NPCR ranged from 0.1 (non-Hodgkin 
lymphoma) to 2.2 (cancers of the brain and other nervous system) percentage points and 
between the United States (SEER and NPCR combined) and Canada from 0.1 (brain and 
other nervous system) to 5.7 (liver and intrahepatic bile duct) percentage points.
Discussion
This study investigated the impact of different follow-up procedures on survival estimates 
using data from 51 NAACCR member registries with high-quality cancer incidence data. 
The analysis showed that for Canadian and NPCR registries that either conducted national 
death linkages or met SEER follow-up standards, survival estimates for all races combined 
appeared to be in the range of the SEER registries, which were considered the gold standard 
because these registries are funded and required to meet standards for reporting timely and 
complete follow-up data, and their survival data are routinely published (24).
However, ensuring the accuracy and comparability of population-based cancer survival can 
be challenging for reasons related to the completeness and quality of the incidence data; the 
procedures used to collect follow-up information; and the assumptions underlying the 
analyses, particularly as relates to known or presumed period of risk of death among cancer 
survivors. In addition, a close examination of survival data can further reveal data quality 
issues not apparent in an examination of incidence data alone.
Incidence Data
First, to ensure accurate and unbiased survival estimates, registries must ascertain all, or 
nearly all, patients diagnosed with cancer in their catchment area (30). In 1997, NAACCR 
instituted a program to evaluate and certify incidence data from member registries. 
Information on evaluation methods and certification criteria has been published (18). 
Considerable progress has been made in increasing the number of registries reporting high-
quality incidence data (31).
Population-based incidence data reflects a mixture of cancers that are diagnosed through 
microscopic confirmation, radiologic imaging, clinical examination, or laboratory 
procedures. As seen in this study, the majority of cases were MC. However, at the very least, 
death clearance should identify a small percentage of clinically confirmed cases, particularly 
among elderly patients and patients with highly fatal cancers, who upon follow back, are 
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found to have a date of diagnosis that precedes their date of death and thus have a calculable 
survival interval. One NPCR registry (NPCR15) reported 100% MC non-DCO cases and 
somewhat higher survival estimates for all four cancers investigated in this study. This 
registry’s higher survival estimates do not appear to result from a lack of death 
ascertainment (they conducted death clearance and NDI linkages and their percentage DCO 
cases was comparable with other registries); instead, these survival estimates may reflect 
selection bias due to an over reliance on pathology laboratories as a case finding source 
and/or the systematic exclusion of clinically confirmed cases with short survival times. This 
registry should review their death clearance procedures and case finding sources and include 
all patients diagnosed with cancer within their state, as characteristic of a population-based 
cancer registry (30). Systematically excluding clinically confirmed cases diminishes the 
registry’s ability to inform population-based cancer control efforts.
Death Ascertainment
Death clearance is primarily intended to identify incident cases that were missed at diagnosis 
and is thus performed throughout or immediately following the end of the current diagnosis 
year. Death clearance also provides an opportunity to update vital status (ie, deaths) among 
registered cancer patients when the linkages are performed using all death certificates, and 
not just those coded to cancer as the underlying cause of death. All cancer registries are 
required to perform death clearance and to update vital status of decedents (12). Linkage 
with local death files identifies the majority of deaths (32). The unusually and consistently 
high survival estimates observed in two NPCR registries (NPCR26 and NPCR31), neither of 
which conducted NDI linkages, suggests that these registries are missing a substantial 
number of deaths, including deaths that could have been found through routine linkage with 
state death records. These registries should review their death clearance procedures to ensure 
that the vital status of registered incident cases that link with state death records (all causes) 
are updated accordingly.
Linkage with local death records may yet miss some deaths that are reported late to the state 
vital statistics office through interstate data exchange agreements, and among patients who 
move out of the state between the time of their diagnosis and their death. Interstate- and 
interprovincial- migration rates are known to vary by jurisdiction (33,34). For this reason, it 
is important for all cancer registries to link with their national death databases. Missing only 
a small number of deaths can result in an overestimation of survival (19,20). This study 
confirmed this finding and showed the importance of ascertaining all, or nearly all, deaths, 
particularly for fatal cancers such as cancers of the lung and bronchus (Figure 1C). NPCR 
registries whose data did not include NDI linkage results tended to report higher survival 
rates than SEER registries, which performed complete follow-up, or Canadian registries, 
which linked with their national death database. Even among NPCR and Canadian registries 
that conducted national death linkages, there was the suggestion that some deaths may yet be 
missing as evidenced by somewhat higher survival estimates for highly fatal cancers such as 
liver and pancreas (Table 3).
Further work is needed to ensure the accuracy of death record linkages. Evaluation of 
“immortals”—patients who are diagnosed with a highly fatal and/or late stage cancer and 
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who are reported alive well beyond their natural life span—may elucidate potential 
problems with death ascertainment, including those resulting from linkage errors owing to 
missing, incomplete, or nonspecific linkage variables. The reluctance of some medical 
facilities to report Social Security numbers and/or birth dates to cancer registries may 
impede the registries’ ability to identify deaths through linkages with state and national 
death certificate files (35). It should also be kept in mind that deaths among patients who 
leave the country will not be ascertained through linkage with local or national death 
certificate databases.
Period at Risk of Death
Having comprehensively ascertained deaths, the question then becomes, what period at risk 
should be used to calculate survival for nondeceased patients–the period that the patient is 
reported to be alive (from the date of diagnosis to the date of last contact as reported by the 
cancer registry) or the period the patient is presumed to be alive (from the date of diagnosis 
to the end of the study period). Systematically underestimating the time that a cancer patient 
is at risk of dying can lower survival estimates (20). As seen in this study, reported alive 
survival estimates were slightly lower than presumed alive estimates for all cancers among 
the SEER registries (Table 3). This was because the survival interval in the reported alive 
survival analysis could be shorter than the survival interval in the presumed alive survival 
analysis.
Cancer registries that conduct complete follow-up to meet SEER follow-up standards are 
expending a great deal of resources updating follow-up information on all patients surviving 
a diagnosis of cancer. As the number of these prevalent cases increases, due to improving 
survival and a growing elderly population in North America (36,37), the burden and cost to 
the cancer registry to maintain complete and timely follow-up information will increase. 
Focusing resources on first identifying all deaths among registered patients before following 
cancer survivors may be a more effective and efficient use of limited resources, especially 
for NPCR registries that are not required nor funded to conduct follow-up activities.
SEER registries have additional information on a somewhat different type of “immortals”—
cancer patients who have a diagnosis date but who immediately became lost to follow-up 
following their diagnosis. This situation can occur if a cancer patient leaves the United 
States immediately following their diagnosis (35). Reported alive survival analyses exclude 
these cases (they were documented with zero follow-up time), whereas presumed alive 
survival analyses include these cases and consider them to be alive at the end of the study 
period. These cases contribute no time at risk of death in the reported alive analysis and 
maximum time at risk of death in the presumed alive analysis. Cancer registries that do not 
conduct complete follow-up will not have knowledge of these “immortal” cancer patients 
and must consider all nondeceased cancer patients to be alive as of the end of the study 
period. For this reason, registries must pay close attention to where the cancer patient 
resided when they were diagnosed to identify nonresidents who were evaluated or treated in 
a medical facility in the registry’s catchment area. Cancer patients who leave the country 
immediately following a diagnosis of cancer (to be with family and/or to obtain treatment 
not available to them where they reside) will be more difficult to identify.
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Incomplete follow-up, including death ascertainment, among certain racial and ethnic 
groups can bias survival estimates (38). In addition, a bias may result among younger cancer 
patients due to lower follow-up rates among these patients (20). The extent and direction of 
theses biases may vary according to primary site, age, and stage.
Limitations
The proportion of cases that were excluded from these analyses ranged from 6.9% (CAN03) 
to 20.5% (SEER04), with the majority of exclusions in all registries due to MP cancers, or 
subsequent cancers. Although it has been routine practice to estimate survival based on first 
primary, non-DCO cancers, this practice may introduce a bias in comparative studies. To 
minimize this bias, Brenner and Hakulinen (39) have suggested that all primary cancers, 
regardless of their sequence number, be included in comparative survival analyses. Work is 
underway to assess the impact of this recommendation on data collected using SEER MP 
rules (40).
RS estimates were calculated for the purpose of comparing different methods of follow-up. 
Survival estimates may over- or under-estimate survival if there is a mismatch between the 
life table and the cancer patient cohort (41). For example, six US registries (three NPCR and 
three SEER) reported prostate survival in excess of 100%, suggesting that survival among 
these cancer patients was higher than the expected survival in the general population. This 
can happen when information on deaths is missing or when cancer patients are successfully 
treated for their cancer and other comorbidities and adopt a healthy lifestyle. It can also 
occur when the life tables do not accurately reflect the background mortality experience of 
the cancer patients. As life expectancy in the United States has been shown to vary by state, 
using national life tables may not be appropriate for all states (42). A comparative analysis 
of national- versus state-specific life tables is presented elsewhere in this monograph (43).
Conclusions
In conclusion, survival data from registries utilizing different follow-up procedures may be 
aggregated and compared across programs and jurisdictions. The choice between using the 
reported alive survival interval or the presumed alive survival interval, or a combination of 
the two, will depend on the groups to be compared and the objective of the analysis.
NAACCR survival data, which currently covers greater than 50% of the populations in the 
United States and Canada, respectively, can make a significant contribution to understanding 
the cancer burden and evaluating cancer control efforts aimed at reducing the burden at the 
national, provincial, state, and local levels.
As NAACCR prepares to include population-based cancer survival estimates in Cancer in 
North America, the following points should be considered, based upon our study results:
1. Complete and high-quality incidence data are essential for accurate survival 
estimates.
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2. Linkage with local (provincial and state) and national death databases for the 
purpose of ascertaining all, or virtually all, deaths among cancer patients should be 
a minimum requirement for survival analyses.
3. The “at-risk” interval for living patients should be based on the best available 
information. If comprehensive death ascertainment has been performed and 
complete follow-up is available (ie, to meet SEER follow-up standards), survival 
should be based on the reported alive method to take advantage of best available 
follow-up information. If complete follow-up information is not available, the 
presumed alive method should be used.
4. To facilitate the interpretation of survival results, data quality indicators should be 
available and include information on the percentage of DCO and MP cancer cases 
and the percentage MC among cases used to estimate survival.
5. Reports of cancer survival should clearly indicate whether the results are based on 
the reported alive method, the presumed alive method, or a combination of both.
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Figure 1. 
Five-year, age-standardized, relative survival using reported alive survival and presumed 
alive survival for cancer patients not known to be deceased for cases diagnosed from 2002 
through 2006 and followed through 2007, by cancer registry (country and funding source): 
female breast (A), prostate (B), lung and bronchus (C), and colorectal (D). *Values that 
were ≥1% above the SEER range. ˆFor some combinations of registry, primary site, and age 
group, no cases were reported alive at the start of the 60th month using reported alive 
survival. To avoid presenting missing survival in this situation, unstandardized estimates 
were used for both reported alive and presumed alive survival. Reported alive survival is 
based on the interval between the date of diagnosis and the follow-up date as reported by the 
registry for nondeceased patients. Presumed alive survival is based on the interval between 
the date of diagnosis and the end-of-study date (December 31, 2007) for nondeceased 
patients.
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